董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David M. Stark | 男 | Director | 56 | 未披露 | 未持股 | 2025-11-03 |
| Sigurd C. Kirk | 男 | Director | 59 | 未披露 | 未持股 | 2025-11-03 |
| Heather L. Mason | 女 | Director | 64 | 未披露 | 未持股 | 2025-11-03 |
| Sravan K. Emany | 男 | Director | -- | 未披露 | 未持股 | 2025-11-03 |
| Brendan P. O'Grady | 男 | Director | -- | 未披露 | 未持股 | 2025-11-03 |
| Mark L. Reisenauer | 男 | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-03 |
| William T. McKee | 男 | Director | 63 | 未披露 | 未持股 | 2025-11-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark L. Reisenauer | 男 | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-03 |
| Ajay Patel | 男 | Executive Vice President and Chief Financial Officer | -- | 未披露 | 未持股 | 2025-11-03 |
| Paul Schwichtenberg | 男 | President and Chief Operating Officer | -- | 未披露 | 未持股 | 2025-11-03 |
| Mary E. Pietryga | 女 | Executive Vice President and Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-11-03 |
| Sam Schlessinger | 男 | Executive Vice President and General Counsel | -- | 未披露 | 未持股 | 2025-11-03 |
董事简历
中英对照 | 中文 | 英文- David M. Stark
-
David M. Stark，他于2016年11月被任命为集团执行副总裁和首席法务官。从2014年到2015年，他曾担任高级副总裁和总法律顾问，负责全球专业药物。2002年加入Teva公司以来，他曾担任Teva North America、Teva Americas的一系列职务，并不断被提拔，其中包括高级主管、副总法律顾问、副总裁兼总法律顾问。加入Teva公司之前，他曾担任Willkie Farr & Gallagher LLP（1998年至2002年）、Chadbourne & Parke（1997年至1998年）、Haight, Gardner, Poor & Havens（1994年至1997年）的诉讼部门的副律师。他持有New York University School of Law的法学博士学位，以及Northeastern University的政治科学学士学位（以优异成绩获得）。
David M. Stark became Executive Vice President, Chief Legal Officer in November 2017. From November 2016 to November 2017 he served as Group Executive Vice President, Chief Legal Officer. From 2014 to 2015 Mr. Stark was Senior Vice President and General Counsel, Global Specialty Medicines. Since joining Teva in 2002 Mr. Stark served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr & Gallagher LLP between 1998 and 2002 Chadbourne & Parke between 1997 and 1998 and Haight, Gardner, Poor & Havens between 1994 and 1997. Mr. Stark received a J.D. from New York University School of Law and a B.A. in political science from Northeastern University, summa cum laude. - David M. Stark，他于2016年11月被任命为集团执行副总裁和首席法务官。从2014年到2015年，他曾担任高级副总裁和总法律顾问，负责全球专业药物。2002年加入Teva公司以来，他曾担任Teva North America、Teva Americas的一系列职务，并不断被提拔，其中包括高级主管、副总法律顾问、副总裁兼总法律顾问。加入Teva公司之前，他曾担任Willkie Farr & Gallagher LLP（1998年至2002年）、Chadbourne & Parke（1997年至1998年）、Haight, Gardner, Poor & Havens（1994年至1997年）的诉讼部门的副律师。他持有New York University School of Law的法学博士学位，以及Northeastern University的政治科学学士学位（以优异成绩获得）。
- David M. Stark became Executive Vice President, Chief Legal Officer in November 2017. From November 2016 to November 2017 he served as Group Executive Vice President, Chief Legal Officer. From 2014 to 2015 Mr. Stark was Senior Vice President and General Counsel, Global Specialty Medicines. Since joining Teva in 2002 Mr. Stark served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr & Gallagher LLP between 1998 and 2002 Chadbourne & Parke between 1997 and 1998 and Haight, Gardner, Poor & Havens between 1994 and 1997. Mr. Stark received a J.D. from New York University School of Law and a B.A. in political science from Northeastern University, summa cum laude.
- Sigurd C. Kirk
-
Sigurd C.Kirk自2021年5月12日起担任董事会成员。Kirk先生是一名高级企业业务开发执行官，在品牌生物制药、医疗器械和非专利产品领域拥有超过15年的制药经验。从2009年到2020年5月被艾伯维公司收购，Kirk先生在Allergan plc.（前身为Actavis）担任多个职位。从2012年5月到2020年5月，Kirk先生担任Allergan plc的企业业务开发执行副总裁，在那里他是12人执行领导团队的成员。他是一个不可或缺的成员，评估发展和商业机会，领导尽职调查，以及谈判和交易关键的法律和金融条款。从2003年到2009年，Kirk先生还担任Barr Pharmaceuticals，Inc.的高级副总裁、全球总会计师和首席会计官。柯克的职业生涯始于德勤会计师事务所（Deloitte&Touche），担任审计经理，并获得了CPA认证。Kirk先生在佩斯大学获得工商管理学士学位。
Sigurd C. Kirk,has served as a member of the Board of Directors since May 12, 2021. Mr. Kirk is a senior corporate business development executive with more than 15 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. From 2009 until its acquisition by AbbVie Inc. in May 2020, Mr. Kirk held various positions at Allergan plc. (formerly Actavis). From May 2012 until May 2020, Mr. Kirk was Executive Vice President, Corporate Business Development at Allergan plc., where he was a member of the 12-person Executive Leadership Team. He was an integral member assessing development and commercial opportunities, leading due diligence, as well as negotiating and transacting key legal and financial terms. Mr. Kirk also served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc. from 2003 until 2009. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification. Mr. Kirk received his Bachelor of Business Administration degree from Pace University. - Sigurd C.Kirk自2021年5月12日起担任董事会成员。Kirk先生是一名高级企业业务开发执行官，在品牌生物制药、医疗器械和非专利产品领域拥有超过15年的制药经验。从2009年到2020年5月被艾伯维公司收购，Kirk先生在Allergan plc.（前身为Actavis）担任多个职位。从2012年5月到2020年5月，Kirk先生担任Allergan plc的企业业务开发执行副总裁，在那里他是12人执行领导团队的成员。他是一个不可或缺的成员，评估发展和商业机会，领导尽职调查，以及谈判和交易关键的法律和金融条款。从2003年到2009年，Kirk先生还担任Barr Pharmaceuticals，Inc.的高级副总裁、全球总会计师和首席会计官。柯克的职业生涯始于德勤会计师事务所（Deloitte&Touche），担任审计经理，并获得了CPA认证。Kirk先生在佩斯大学获得工商管理学士学位。
- Sigurd C. Kirk,has served as a member of the Board of Directors since May 12, 2021. Mr. Kirk is a senior corporate business development executive with more than 15 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. From 2009 until its acquisition by AbbVie Inc. in May 2020, Mr. Kirk held various positions at Allergan plc. (formerly Actavis). From May 2012 until May 2020, Mr. Kirk was Executive Vice President, Corporate Business Development at Allergan plc., where he was a member of the 12-person Executive Leadership Team. He was an integral member assessing development and commercial opportunities, leading due diligence, as well as negotiating and transacting key legal and financial terms. Mr. Kirk also served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc. from 2003 until 2009. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification. Mr. Kirk received his Bachelor of Business Administration degree from Pace University.
- Heather L. Mason
-
Heather L. Mason自2020年起担任Immatics N.V.监事会成员。从1990年到2017年，Mason女士在雅培公司担任过多个领导职位，包括雅培营养执行副总裁、公司官员以及雅培糖尿病护理高级副总裁、公司官员。除Immatics N.V.监事会外，Mason女士还担任Assertio Therapeutics, Inc. ConvaTec Group plc、Pendulum Therapeutics，Inc.和SCA Pharmaceuticals，LLC的董事会成员。Mason女士拥有B.S.E.来自密歇根大学安娜堡分校和芝加哥大学的工商管理硕士学位。
Heather L. Mason has served as a member of Immatics N.V. Supervisory Board since 2020. From 1990 to 2017 Ms. Mason served in various leadership positions at Abbott Laboratories, Inc., including as Executive Vice President, Corporate Officer of Abbott Nutrition and as Senior Vice President, Corporate Officer of Abbott Diabetes Care. In addition to Immatics N.V. Supervisory Board, Ms. Mason serves on the board of directors of Assertio Therapeutics, Inc. ConvaTec Group plc, Pendulum Therapeutics, Inc. and SCA Pharmaceuticals, LLC. Ms. Mason holds a B.S.E. from the University of Michigan, Ann Arbor and an M.B.A. from the University of Chicago. - Heather L. Mason自2020年起担任Immatics N.V.监事会成员。从1990年到2017年，Mason女士在雅培公司担任过多个领导职位，包括雅培营养执行副总裁、公司官员以及雅培糖尿病护理高级副总裁、公司官员。除Immatics N.V.监事会外，Mason女士还担任Assertio Therapeutics, Inc. ConvaTec Group plc、Pendulum Therapeutics，Inc.和SCA Pharmaceuticals，LLC的董事会成员。Mason女士拥有B.S.E.来自密歇根大学安娜堡分校和芝加哥大学的工商管理硕士学位。
- Heather L. Mason has served as a member of Immatics N.V. Supervisory Board since 2020. From 1990 to 2017 Ms. Mason served in various leadership positions at Abbott Laboratories, Inc., including as Executive Vice President, Corporate Officer of Abbott Nutrition and as Senior Vice President, Corporate Officer of Abbott Diabetes Care. In addition to Immatics N.V. Supervisory Board, Ms. Mason serves on the board of directors of Assertio Therapeutics, Inc. ConvaTec Group plc, Pendulum Therapeutics, Inc. and SCA Pharmaceuticals, LLC. Ms. Mason holds a B.S.E. from the University of Michigan, Ann Arbor and an M.B.A. from the University of Chicago.
- Sravan K. Emany
-
Sravan K. Emany，自2023年11月起担任公司董事，并自2024年12月起担任纳斯达克上市生物技术公司Beam Therapeutics Inc.的高级副总裁兼首席财务官。在加入Beam之前，Emany先生曾于2021年12月至2024年12月期间在医疗保健上市公司Ironwood Pharmaceuticals, Inc.担任高级副总裁兼首席财务官。在加入Ironwood之前，Emany先生于2020年3月至2021年12月期间担任Integra LifeSciences Holdings Corporation（一家全球医疗保健上市公司）的企业副总裁、商业卓越和首席战略官，并于2018年2月至2020年3月期间担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾于2008年9月至2018年2月在美国银行和美国银行证券（前美银美林）担任多个并购投资银行职务，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。Emany先生还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。
Sravan K. Emany,has served as a director of the Company since November 2023 and has served as Senior Vice President and Chief Financial Officer of Beam Therapeutics Inc., a Nasdaq listed biotechnology company, since December 2024. Prior to joining Beam, Mr. Emany served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc., a Nasdaq listed healthcare company, from December 2021 until December 2024. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley.Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies. - Sravan K. Emany，自2023年11月起担任公司董事，并自2024年12月起担任纳斯达克上市生物技术公司Beam Therapeutics Inc.的高级副总裁兼首席财务官。在加入Beam之前，Emany先生曾于2021年12月至2024年12月期间在医疗保健上市公司Ironwood Pharmaceuticals, Inc.担任高级副总裁兼首席财务官。在加入Ironwood之前，Emany先生于2020年3月至2021年12月期间担任Integra LifeSciences Holdings Corporation（一家全球医疗保健上市公司）的企业副总裁、商业卓越和首席战略官，并于2018年2月至2020年3月期间担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾于2008年9月至2018年2月在美国银行和美国银行证券（前美银美林）担任多个并购投资银行职务，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。Emany先生还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。
- Sravan K. Emany,has served as a director of the Company since November 2023 and has served as Senior Vice President and Chief Financial Officer of Beam Therapeutics Inc., a Nasdaq listed biotechnology company, since December 2024. Prior to joining Beam, Mr. Emany served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc., a Nasdaq listed healthcare company, from December 2021 until December 2024. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley.Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
- Brendan P. O'Grady
-
Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University. - Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
- Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University.
- Mark L. Reisenauer
-
Mark L. Reisenauer，自2025年1月起担任公司董事。Reisenauer先生于2021年4月至2024年4月在全球生命科学公司Astellas Pharmaceuticals Inc.担任美国商业总裁，在此之前，于2011年4月至2021年4月担任肿瘤业务部门高级副总裁。在加入安斯泰来之前，Reisenauer先生曾于2007年9月至2011年4月在Micromet Inc.担任高级副总裁兼首席商务官，该公司是一家生物技术公司，后来被安进公司收购。在加入Micromet之前，Reisenauer先生曾于2002年5月至2007年9月在跨国医疗器械和保健公司雅培担任部门副总裁兼神经科学总经理，在此之前，担任肿瘤学总经理。在其职业生涯的早期，Reisenauer先生曾在Pharmacia Corporation、百时美施贵宝和Zeneca Pharmaceuticals任职。Reisenauer先生自2024年起担任Autolus Therapeutics的商业发射和医疗事务顾问委员会成员，此前曾于2021年至2024年期间担任PhRMA贸易协会的董事会成员。Reisenauer先生拥有威斯康星大学政治学学士学位。
Mark L. Reisenauer,has served as a director of the Company since January 2025. Mr. Reisenauer served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., a global life sciences company, from April 2021 to April 2024 and, before that, as Senior Vice President, Oncology Business Unit from April 2011 to April 2021. Prior to joining Astellas, Mr. Reisenauer served as Senior Vice President, Chief Commercial Officer at Micromet Inc., a biotechnology company that was later acquired by Amgen Inc., from September 2007 to April 2011. Prior to Micromet, Mr. Reisenauer served as Divisional Vice President and General Manager, Neuroscience and, before that, General Manager, Oncology, at Abbott Laboratories, a multinational medical devices and health care company, from May 2002 to September 2007. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. Mr. Reisenauer has served as a member of the Commercial Launch and Medical Affairs Advisory Board of Autolus Therapeutics since 2024 and previously served as a member of the board of directors of the PhRMA Trade Association from 2021 to 2024.Mr. Reisenauer holds a B.A. in Political Science from the University of Wisconsin. - Mark L. Reisenauer，自2025年1月起担任公司董事。Reisenauer先生于2021年4月至2024年4月在全球生命科学公司Astellas Pharmaceuticals Inc.担任美国商业总裁，在此之前，于2011年4月至2021年4月担任肿瘤业务部门高级副总裁。在加入安斯泰来之前，Reisenauer先生曾于2007年9月至2011年4月在Micromet Inc.担任高级副总裁兼首席商务官，该公司是一家生物技术公司，后来被安进公司收购。在加入Micromet之前，Reisenauer先生曾于2002年5月至2007年9月在跨国医疗器械和保健公司雅培担任部门副总裁兼神经科学总经理，在此之前，担任肿瘤学总经理。在其职业生涯的早期，Reisenauer先生曾在Pharmacia Corporation、百时美施贵宝和Zeneca Pharmaceuticals任职。Reisenauer先生自2024年起担任Autolus Therapeutics的商业发射和医疗事务顾问委员会成员，此前曾于2021年至2024年期间担任PhRMA贸易协会的董事会成员。Reisenauer先生拥有威斯康星大学政治学学士学位。
- Mark L. Reisenauer,has served as a director of the Company since January 2025. Mr. Reisenauer served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., a global life sciences company, from April 2021 to April 2024 and, before that, as Senior Vice President, Oncology Business Unit from April 2011 to April 2021. Prior to joining Astellas, Mr. Reisenauer served as Senior Vice President, Chief Commercial Officer at Micromet Inc., a biotechnology company that was later acquired by Amgen Inc., from September 2007 to April 2011. Prior to Micromet, Mr. Reisenauer served as Divisional Vice President and General Manager, Neuroscience and, before that, General Manager, Oncology, at Abbott Laboratories, a multinational medical devices and health care company, from May 2002 to September 2007. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. Mr. Reisenauer has served as a member of the Commercial Launch and Medical Affairs Advisory Board of Autolus Therapeutics since 2024 and previously served as a member of the board of directors of the PhRMA Trade Association from 2021 to 2024.Mr. Reisenauer holds a B.A. in Political Science from the University of Wisconsin.
- William T. McKee
-
William T. McKee，于2014年1月起在天蓝制药公司的董事会任职，于2014年3月起在Agile疗法有限公司的董事会任职。他从2010年7月起担任EKR疗法有限公司的首席运营官和首席财务官，直到2012年6月EKR被卖给Cornerstone 疗法有限公司。他也是一家咨询公司MBJC Associates有限责任公司的所有人。直到2010年3月，他担任梯瓦制药产业有限公司的子公司巴尔制药公司的执行副总裁兼首席财务官；该公司也是巴尔制药有限公司的继任者实体，在纽交所上市，于2008年12月被梯瓦公司收购。在巴尔被梯瓦公司收购前，他从1995年起也曾是巴尔执行副总裁和首席财务官，后担任职位的责任也越来越大，直到巴尔被收购。加入巴尔之前，他从1993年6月到1994年12月担任绝对娱乐有限公司国际业务主管和副总裁。他从1990年到1993年6月在Gramkow & Carnevale 工作，从1983年到1990年在德勤工作。他持有圣母大学工商管理学士学位。
William T. McKee,has served as a director of the Company since March 2017. Mr. McKee has served as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving pharmaceutical and biotech companies, since February 2010. Mr. McKee served as Chief Financial Officer of C4 Therapeutics, Inc., a biopharmaceutical company, from July 2020 until June 2021. Mr. McKee served as Chief Operating Officer and Chief Financial Officer for EKR Therapeutics, Inc., from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. Until March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries Limited, and the successor entity to Barr Pharmaceuticals, Inc., which was acquired by Teva in December 2008. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr from 1995 until its acquisition. Mr. McKee serves as a Venture Partner for Cobro Ventures, a private investment firm focused on software and biotech, and a board member of its privately-held portfolio company, NextRNA Therapeutics. He also serves as a board member of privately-held MedRhythms, Inc. From June 2019 to October 2023, Mr. McKee served as a director and chair of the audit committee of Aileron Therapeutics, Inc., a publicly-held biopharmaceutical company. From 2014 to June 2020, Mr. McKee served as a director and member of the audit and compensation committees of Agile Therapeutics, Inc., a publicly-held specialty biopharmaceutical company. From June 2020 to June 2023, Mr. McKee also served as a director of privately-held Vinci Therapeutics.Mr. McKee holds a B.B.A. from the University of Notre Dame and is NACD Directorship Certified and also holds the CERT Certificate in Cyber-Risk Oversight from NACD. - William T. McKee，于2014年1月起在天蓝制药公司的董事会任职，于2014年3月起在Agile疗法有限公司的董事会任职。他从2010年7月起担任EKR疗法有限公司的首席运营官和首席财务官，直到2012年6月EKR被卖给Cornerstone 疗法有限公司。他也是一家咨询公司MBJC Associates有限责任公司的所有人。直到2010年3月，他担任梯瓦制药产业有限公司的子公司巴尔制药公司的执行副总裁兼首席财务官；该公司也是巴尔制药有限公司的继任者实体，在纽交所上市，于2008年12月被梯瓦公司收购。在巴尔被梯瓦公司收购前，他从1995年起也曾是巴尔执行副总裁和首席财务官，后担任职位的责任也越来越大，直到巴尔被收购。加入巴尔之前，他从1993年6月到1994年12月担任绝对娱乐有限公司国际业务主管和副总裁。他从1990年到1993年6月在Gramkow & Carnevale 工作，从1983年到1990年在德勤工作。他持有圣母大学工商管理学士学位。
- William T. McKee,has served as a director of the Company since March 2017. Mr. McKee has served as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving pharmaceutical and biotech companies, since February 2010. Mr. McKee served as Chief Financial Officer of C4 Therapeutics, Inc., a biopharmaceutical company, from July 2020 until June 2021. Mr. McKee served as Chief Operating Officer and Chief Financial Officer for EKR Therapeutics, Inc., from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. Until March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries Limited, and the successor entity to Barr Pharmaceuticals, Inc., which was acquired by Teva in December 2008. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr from 1995 until its acquisition. Mr. McKee serves as a Venture Partner for Cobro Ventures, a private investment firm focused on software and biotech, and a board member of its privately-held portfolio company, NextRNA Therapeutics. He also serves as a board member of privately-held MedRhythms, Inc. From June 2019 to October 2023, Mr. McKee served as a director and chair of the audit committee of Aileron Therapeutics, Inc., a publicly-held biopharmaceutical company. From 2014 to June 2020, Mr. McKee served as a director and member of the audit and compensation committees of Agile Therapeutics, Inc., a publicly-held specialty biopharmaceutical company. From June 2020 to June 2023, Mr. McKee also served as a director of privately-held Vinci Therapeutics.Mr. McKee holds a B.B.A. from the University of Notre Dame and is NACD Directorship Certified and also holds the CERT Certificate in Cyber-Risk Oversight from NACD.
高管简历
中英对照 | 中文 | 英文- Mark L. Reisenauer
Mark L. Reisenauer，自2025年1月起担任公司董事。Reisenauer先生于2021年4月至2024年4月在全球生命科学公司Astellas Pharmaceuticals Inc.担任美国商业总裁，在此之前，于2011年4月至2021年4月担任肿瘤业务部门高级副总裁。在加入安斯泰来之前，Reisenauer先生曾于2007年9月至2011年4月在Micromet Inc.担任高级副总裁兼首席商务官，该公司是一家生物技术公司，后来被安进公司收购。在加入Micromet之前，Reisenauer先生曾于2002年5月至2007年9月在跨国医疗器械和保健公司雅培担任部门副总裁兼神经科学总经理，在此之前，担任肿瘤学总经理。在其职业生涯的早期，Reisenauer先生曾在Pharmacia Corporation、百时美施贵宝和Zeneca Pharmaceuticals任职。Reisenauer先生自2024年起担任Autolus Therapeutics的商业发射和医疗事务顾问委员会成员，此前曾于2021年至2024年期间担任PhRMA贸易协会的董事会成员。Reisenauer先生拥有威斯康星大学政治学学士学位。
Mark L. Reisenauer,has served as a director of the Company since January 2025. Mr. Reisenauer served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., a global life sciences company, from April 2021 to April 2024 and, before that, as Senior Vice President, Oncology Business Unit from April 2011 to April 2021. Prior to joining Astellas, Mr. Reisenauer served as Senior Vice President, Chief Commercial Officer at Micromet Inc., a biotechnology company that was later acquired by Amgen Inc., from September 2007 to April 2011. Prior to Micromet, Mr. Reisenauer served as Divisional Vice President and General Manager, Neuroscience and, before that, General Manager, Oncology, at Abbott Laboratories, a multinational medical devices and health care company, from May 2002 to September 2007. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. Mr. Reisenauer has served as a member of the Commercial Launch and Medical Affairs Advisory Board of Autolus Therapeutics since 2024 and previously served as a member of the board of directors of the PhRMA Trade Association from 2021 to 2024.Mr. Reisenauer holds a B.A. in Political Science from the University of Wisconsin.- Mark L. Reisenauer，自2025年1月起担任公司董事。Reisenauer先生于2021年4月至2024年4月在全球生命科学公司Astellas Pharmaceuticals Inc.担任美国商业总裁，在此之前，于2011年4月至2021年4月担任肿瘤业务部门高级副总裁。在加入安斯泰来之前，Reisenauer先生曾于2007年9月至2011年4月在Micromet Inc.担任高级副总裁兼首席商务官，该公司是一家生物技术公司，后来被安进公司收购。在加入Micromet之前，Reisenauer先生曾于2002年5月至2007年9月在跨国医疗器械和保健公司雅培担任部门副总裁兼神经科学总经理，在此之前，担任肿瘤学总经理。在其职业生涯的早期，Reisenauer先生曾在Pharmacia Corporation、百时美施贵宝和Zeneca Pharmaceuticals任职。Reisenauer先生自2024年起担任Autolus Therapeutics的商业发射和医疗事务顾问委员会成员，此前曾于2021年至2024年期间担任PhRMA贸易协会的董事会成员。Reisenauer先生拥有威斯康星大学政治学学士学位。
- Mark L. Reisenauer,has served as a director of the Company since January 2025. Mr. Reisenauer served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., a global life sciences company, from April 2021 to April 2024 and, before that, as Senior Vice President, Oncology Business Unit from April 2011 to April 2021. Prior to joining Astellas, Mr. Reisenauer served as Senior Vice President, Chief Commercial Officer at Micromet Inc., a biotechnology company that was later acquired by Amgen Inc., from September 2007 to April 2011. Prior to Micromet, Mr. Reisenauer served as Divisional Vice President and General Manager, Neuroscience and, before that, General Manager, Oncology, at Abbott Laboratories, a multinational medical devices and health care company, from May 2002 to September 2007. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. Mr. Reisenauer has served as a member of the Commercial Launch and Medical Affairs Advisory Board of Autolus Therapeutics since 2024 and previously served as a member of the board of directors of the PhRMA Trade Association from 2021 to 2024.Mr. Reisenauer holds a B.A. in Political Science from the University of Wisconsin.
- Ajay Patel
Ajay Patel，自2025年3月1日起担任执行副总裁兼首席财务官，此前自2023年11月起担任高级副总裁兼首席财务官。此前自2021年3月起担任高级副总裁兼首席会计官，自2019年7月入职公司起担任副总裁、财务总监。在加入公司之前，2018年2月至2019年7月，他在食品服务分销商US Foods担任技术会计和会计政策总监，负责建立和维护全公司的会计政策。2006年6月至2018年2月，Patel先生在跨国专业服务网络安永会计师事务所（Ernst & Young）任职，在其鉴证业务中担任各种角色，在领导战略关键客户的财务报表审计方面承担越来越多的责任。Patel先生拥有伊利诺伊大学金融学学士学位，弗吉尼亚大学会计学硕士学位，注册会计师。
Ajay Patel,has served as Executive Vice President and Chief Financial Officer since March 1, 2025, and previously served as Senior Vice President and Chief Financial Officer since November 2023. He previously served as Senior Vice President and Chief Accounting Officer from March 2021 and as Vice President, Controller from July 2019 when he joined the Company. Prior to joining the Company, from February 2018 to July 2019 he served as Director, Technical Accounting & Accounting Policy at US Foods, a food service distributor, where he was responsible for establishing and maintaining company-wide accounting policies. From June 2006 to February 2018, Mr. Patel served at Ernst & Young LLP (Ernst & Young), a multinational professional services network, in various roles of increasing responsibility in its Assurance practice leading financial statement audits of strategic key clients. Mr. Patel holds a B.S. degree in Finance from the University of Illinois, a Masters degree in accounting from the University of Virginia and is a CPA.- Ajay Patel，自2025年3月1日起担任执行副总裁兼首席财务官，此前自2023年11月起担任高级副总裁兼首席财务官。此前自2021年3月起担任高级副总裁兼首席会计官，自2019年7月入职公司起担任副总裁、财务总监。在加入公司之前，2018年2月至2019年7月，他在食品服务分销商US Foods担任技术会计和会计政策总监，负责建立和维护全公司的会计政策。2006年6月至2018年2月，Patel先生在跨国专业服务网络安永会计师事务所（Ernst & Young）任职，在其鉴证业务中担任各种角色，在领导战略关键客户的财务报表审计方面承担越来越多的责任。Patel先生拥有伊利诺伊大学金融学学士学位，弗吉尼亚大学会计学硕士学位，注册会计师。
- Ajay Patel,has served as Executive Vice President and Chief Financial Officer since March 1, 2025, and previously served as Senior Vice President and Chief Financial Officer since November 2023. He previously served as Senior Vice President and Chief Accounting Officer from March 2021 and as Vice President, Controller from July 2019 when he joined the Company. Prior to joining the Company, from February 2018 to July 2019 he served as Director, Technical Accounting & Accounting Policy at US Foods, a food service distributor, where he was responsible for establishing and maintaining company-wide accounting policies. From June 2006 to February 2018, Mr. Patel served at Ernst & Young LLP (Ernst & Young), a multinational professional services network, in various roles of increasing responsibility in its Assurance practice leading financial statement audits of strategic key clients. Mr. Patel holds a B.S. degree in Finance from the University of Illinois, a Masters degree in accounting from the University of Virginia and is a CPA.
- Paul Schwichtenberg
Paul Schwichtenberg，自2025年3月1日起担任执行副总裁兼首席转型官，此前自2024年12月起担任高级副总裁兼首席转型官。他此前自2024年2月起担任高级副总裁兼商务官，在此之前，自2023年11月起担任商业定价、分析和分销高级副总裁，自2021年3月起担任高级副总裁、首席财务官，自2018年4月加入公司起担任财务副总裁。在加入公司之前，他曾于2013年10月至2018年4月担任生物制药公司艾伯维（AbbVie）的定价和规划总监，领导美国商业定价团队。在此之前，Schwichtenberg先生于2010年10月至2013年10月担任消费产品公司Radio Flyer，Inc.的财务总监。从2000年到2010年10月，Schwichtenberg先生在武田制药担任各种职责日益增加的职务，最近担任高级董事和财务总监。在进入制药行业之前，他曾在Wolf & Company LLP担任高级审计师。Schwichtenberg先生拥有罗斯福大学工商管理学士学位，是一名注册会计师。
Paul Schwichtenberg,has served as Executive Vice President and Chief Transformation Officer since March 1, 2025, and previously served as Senior Vice President and Chief Transformation Officer since December 2024. He previously served as Senior Vice President and Commercial Officer since February 2024, prior to which he served as Senior Vice President, Commercial Pricing, Analytics and Distribution from November 2023, as Senior Vice President, Chief Financial Officer from March 2021, and as Vice President, Finance from April 2018 when he joined the Company. Prior to joining the Company, he served as Director of Pricing and Planning for AbbVie, a biopharmaceutical company, from October 2013 to April 2018 where he led the U.S. Commercial Pricing Team. Prior to this, Mr. Schwichtenberg served as Controller for Radio Flyer, Inc., a consumer products company, from October 2010 to October 2013. From 2000 to October 2010, Mr. Schwichtenberg served at Takeda Pharmaceuticals in various roles of increasing responsibility, most recently as Senior Director and Controller. Prior to entering the pharmaceutical industry, he served as a senior auditor at Wolf & Company LLP. Mr. Schwichtenberg holds a B.S. degree in Business Administration from Roosevelt University and is a CPA.- Paul Schwichtenberg，自2025年3月1日起担任执行副总裁兼首席转型官，此前自2024年12月起担任高级副总裁兼首席转型官。他此前自2024年2月起担任高级副总裁兼商务官，在此之前，自2023年11月起担任商业定价、分析和分销高级副总裁，自2021年3月起担任高级副总裁、首席财务官，自2018年4月加入公司起担任财务副总裁。在加入公司之前，他曾于2013年10月至2018年4月担任生物制药公司艾伯维（AbbVie）的定价和规划总监，领导美国商业定价团队。在此之前，Schwichtenberg先生于2010年10月至2013年10月担任消费产品公司Radio Flyer，Inc.的财务总监。从2000年到2010年10月，Schwichtenberg先生在武田制药担任各种职责日益增加的职务，最近担任高级董事和财务总监。在进入制药行业之前，他曾在Wolf & Company LLP担任高级审计师。Schwichtenberg先生拥有罗斯福大学工商管理学士学位，是一名注册会计师。
- Paul Schwichtenberg,has served as Executive Vice President and Chief Transformation Officer since March 1, 2025, and previously served as Senior Vice President and Chief Transformation Officer since December 2024. He previously served as Senior Vice President and Commercial Officer since February 2024, prior to which he served as Senior Vice President, Commercial Pricing, Analytics and Distribution from November 2023, as Senior Vice President, Chief Financial Officer from March 2021, and as Vice President, Finance from April 2018 when he joined the Company. Prior to joining the Company, he served as Director of Pricing and Planning for AbbVie, a biopharmaceutical company, from October 2013 to April 2018 where he led the U.S. Commercial Pricing Team. Prior to this, Mr. Schwichtenberg served as Controller for Radio Flyer, Inc., a consumer products company, from October 2010 to October 2013. From 2000 to October 2010, Mr. Schwichtenberg served at Takeda Pharmaceuticals in various roles of increasing responsibility, most recently as Senior Director and Controller. Prior to entering the pharmaceutical industry, he served as a senior auditor at Wolf & Company LLP. Mr. Schwichtenberg holds a B.S. degree in Business Administration from Roosevelt University and is a CPA.
- Mary E. Pietryga
Mary E. Pietryga，自2025年3月1日起担任执行副总裁兼首席商务官，此前自2024年12月起担任高级副总裁兼首席商务官。她于2025年2月成为该公司的执行官。Mary是一位经验丰富的企业高管，拥有制药/生物科学和医疗器械行业的多元化背景。她的领导涵盖商业销售、付款人准入和定价以及战略营销。在加入公司之前，她于2024年2月至2024年12月担任Teva Pharmaceuticals Industries Ltd.副总裁兼全球生物仿制药投资组合负责人，负责重新设计全球资产投资组合并创建一个多年框架，以增加收入并推动新的合作伙伴关系。在此之前，她在制药公司担任过多个职位，包括2021年3月至2024年1月在Peregrine Market Access担任合伙人、首席商务官，负责领导合同团队交付端到端、完全集成的CRO和商业解决方案；2019年4月至2021年1月在Pacira Biosciences Inc.担任疼痛特许经营市场营销副总裁；2017年7月至2019年3月在Ferring Pharmaceutical担任胃肠病学和泌尿系统肿瘤学特许经营业务部门负责人。在此之前，她曾在赛诺菲（负责国内和全球事务）、默沙东公司任职。Pietryga女士拥有密歇根州立大学数学教育学士学位和维拉诺瓦大学工商管理硕士学位。
Mary E. Pietryga,has served as Executive Vice President and Chief Commercial Officer since March 1, 2025, and previously served as Senior Vice President and Chief Commercial Officer since December 2024. She became an executive officer of the Company in February 2025. Mary is an experienced business executive with a diversified background in the pharmaceutical/bioscience and medical device industry. Her leadership spans commercial sales, payer access and pricing, and strategic marketing. Before joining the Company, she was Vice President, Head of Global Biosimilar Portfolio at Teva Pharmaceuticals Industries Ltd. from February 2024 to December 2024 where she was responsible for the redesign of the global asset portfolio and creation of a multi-year framework to increase revenue and drive new partnerships. Prior to that she held a number of positions at pharmaceutical companies including as a Partner, Chief Commercial Officer at Peregrine Market Access from March 2021 to January 2024, where she was responsible for leading contract teams to deliver end-to-end, fully integrated, CRO and commercial solutions; Vice President, Marketing, Pain Franchise at Pacira Biosciences Inc. from April 2019 through January 2021; and Business Unit Head, Gastroenterology & Uro Oncology Franchises at Ferring Pharmaceutical from July 2017 through March 2019. Prior to that, she held positions at Sanofi (Domestic and Global responsibilities), and Merck & Co. Ms. Pietryga holds a bachelor's degree in Mathematics Education from Michigan State University and a Master of Business Administration from Villanova University.- Mary E. Pietryga，自2025年3月1日起担任执行副总裁兼首席商务官，此前自2024年12月起担任高级副总裁兼首席商务官。她于2025年2月成为该公司的执行官。Mary是一位经验丰富的企业高管，拥有制药/生物科学和医疗器械行业的多元化背景。她的领导涵盖商业销售、付款人准入和定价以及战略营销。在加入公司之前，她于2024年2月至2024年12月担任Teva Pharmaceuticals Industries Ltd.副总裁兼全球生物仿制药投资组合负责人，负责重新设计全球资产投资组合并创建一个多年框架，以增加收入并推动新的合作伙伴关系。在此之前，她在制药公司担任过多个职位，包括2021年3月至2024年1月在Peregrine Market Access担任合伙人、首席商务官，负责领导合同团队交付端到端、完全集成的CRO和商业解决方案；2019年4月至2021年1月在Pacira Biosciences Inc.担任疼痛特许经营市场营销副总裁；2017年7月至2019年3月在Ferring Pharmaceutical担任胃肠病学和泌尿系统肿瘤学特许经营业务部门负责人。在此之前，她曾在赛诺菲（负责国内和全球事务）、默沙东公司任职。Pietryga女士拥有密歇根州立大学数学教育学士学位和维拉诺瓦大学工商管理硕士学位。
- Mary E. Pietryga,has served as Executive Vice President and Chief Commercial Officer since March 1, 2025, and previously served as Senior Vice President and Chief Commercial Officer since December 2024. She became an executive officer of the Company in February 2025. Mary is an experienced business executive with a diversified background in the pharmaceutical/bioscience and medical device industry. Her leadership spans commercial sales, payer access and pricing, and strategic marketing. Before joining the Company, she was Vice President, Head of Global Biosimilar Portfolio at Teva Pharmaceuticals Industries Ltd. from February 2024 to December 2024 where she was responsible for the redesign of the global asset portfolio and creation of a multi-year framework to increase revenue and drive new partnerships. Prior to that she held a number of positions at pharmaceutical companies including as a Partner, Chief Commercial Officer at Peregrine Market Access from March 2021 to January 2024, where she was responsible for leading contract teams to deliver end-to-end, fully integrated, CRO and commercial solutions; Vice President, Marketing, Pain Franchise at Pacira Biosciences Inc. from April 2019 through January 2021; and Business Unit Head, Gastroenterology & Uro Oncology Franchises at Ferring Pharmaceutical from July 2017 through March 2019. Prior to that, she held positions at Sanofi (Domestic and Global responsibilities), and Merck & Co. Ms. Pietryga holds a bachelor's degree in Mathematics Education from Michigan State University and a Master of Business Administration from Villanova University.
- Sam Schlessinger
Sam Schlessinger，自2025年3月1日起担任执行副总裁兼总法律顾问，此前自2021年7月起担任高级副总裁兼总法律顾问。他于2022年3月成为公司的执行官。Schlessinger先生此前曾于2021年2月至2021年6月担任公司副总裁兼法律部，并于2020年5月至2021年2月担任高级法律顾问。在加入公司之前，Schlessinger先生于2019年至2020年期间通过Axiom Law为公司提供外包的公司和证券法律服务。在此之前，他曾于2015年至2018年在Dentons LLP担任企业合伙人，在并购、收购和资本重组以及证券交易方面为公共和私营客户提供咨询；2012年至2015年在Dentons LLP担任企业合伙人；2006年至2012年在McDermott Will & Emery LLP担任企业合伙人。Schlessinger先生拥有波莫纳学院的数学学士学位和伊利诺伊大学的京东。
Sam Schlessinger,has served as Executive Vice President and General Counsel since March 1, 2025, and previously served as Senior Vice President and General Counsel since July 2021. He became an executive officer of the Company in March 2022. Mr. Schlessinger previously served as the Company's Vice President,Legal from February 2021 through June 2021 and as Senior Counsel from May 2020 to February 2021. Prior to joining the Company, Mr. Schlessinger provided outsourced corporate and securities legal services to the Company from 2019 to 2020 through Axiom Law. Prior to that, he served as a corporate partner at Dentons LLP from 2015 to 2018, where he advised public and privately- held clients in mergers and acquisitions, buyouts and recapitalizations, and securities transactions; a corporate associate at Dentons LLP from 2012 to 2015; and a corporate associate at McDermott Will & Emery LLP from 2006 to 2012. Mr. Schlessinger holds a B.A. degree in Mathematics from Pomona College and a JD from the University of Illinois.- Sam Schlessinger，自2025年3月1日起担任执行副总裁兼总法律顾问，此前自2021年7月起担任高级副总裁兼总法律顾问。他于2022年3月成为公司的执行官。Schlessinger先生此前曾于2021年2月至2021年6月担任公司副总裁兼法律部，并于2020年5月至2021年2月担任高级法律顾问。在加入公司之前，Schlessinger先生于2019年至2020年期间通过Axiom Law为公司提供外包的公司和证券法律服务。在此之前，他曾于2015年至2018年在Dentons LLP担任企业合伙人，在并购、收购和资本重组以及证券交易方面为公共和私营客户提供咨询；2012年至2015年在Dentons LLP担任企业合伙人；2006年至2012年在McDermott Will & Emery LLP担任企业合伙人。Schlessinger先生拥有波莫纳学院的数学学士学位和伊利诺伊大学的京东。
- Sam Schlessinger,has served as Executive Vice President and General Counsel since March 1, 2025, and previously served as Senior Vice President and General Counsel since July 2021. He became an executive officer of the Company in March 2022. Mr. Schlessinger previously served as the Company's Vice President,Legal from February 2021 through June 2021 and as Senior Counsel from May 2020 to February 2021. Prior to joining the Company, Mr. Schlessinger provided outsourced corporate and securities legal services to the Company from 2019 to 2020 through Axiom Law. Prior to that, he served as a corporate partner at Dentons LLP from 2015 to 2018, where he advised public and privately- held clients in mergers and acquisitions, buyouts and recapitalizations, and securities transactions; a corporate associate at Dentons LLP from 2012 to 2015; and a corporate associate at McDermott Will & Emery LLP from 2006 to 2012. Mr. Schlessinger holds a B.A. degree in Mathematics from Pomona College and a JD from the University of Illinois.